statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Edesa Biotech to Participate in Upcoming Investor Conferences

TORONTO, ON / ACCESSWIRE / April 2, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...

Pardeep Nijhawan Acquires 5,000 Shares of Edesa Biotech, Inc. (NASDAQ:EDSA) Stock

Edesa Biotech, Inc. (NASDAQ:EDSA  Get Free Report) CEO Pardeep Nijhawan purchased 5,000 shares of the companys stock in a transaction dated Monday, March 25th. The shares were bought at...

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference

TORONTO, ON / ACCESSWIRE / March 21, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...

Edesa Biotech to Participate in Barclays Global Healthcare Conference

TORONTO, ON / ACCESSWIRE / March 7, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...

Edesa Biotech to Participate in Upcoming Dermatology Meetings

TORONTO, ON / ACCESSWIRE / March 4, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...

Edesa Biotech, Inc. Forecasted to Earn Q2 2024 Earnings of ($0.61) Per Share (NASDAQ:EDSA)

Edesa Biotech, Inc. (NASDAQ:EDSA  Free Report)  Research analysts at HC Wainwright issued their Q2 2024 EPS estimates for shares of Edesa Biotech in a research note issued to investors...

Edesa Biotech (NASDAQ:EDSA) Earns "Buy" Rating from HC Wainwright

Edesa Biotech (NASDAQ:EDSA  Get Free Report)s stock had its buy rating restated by research analysts at HC Wainwright in a research report issued to clients and investors...

Edesa Biotech Reports Fiscal 1st Quarter 2024 Results

TORONTO, ON / ACCESSWIRE / February 9, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...

Brookline Capital Management Comments on Edesa Biotech, Inc.'s Q1 2024 Earnings (NASDAQ:EDSA)

Edesa Biotech, Inc. (NASDAQ:EDSA  Free Report)  Equities researchers at Brookline Capital Management issued their Q1 2024 earnings per share estimates for shares of Edesa Biotech in a...

Research Analysts Issue Forecasts for Edesa Biotech, Inc.'s Q1 2024 Earnings (NASDAQ:EDSA)

Edesa Biotech, Inc. (NASDAQ:EDSA  Free Report)  Zacks Small Cap issued their Q1 2024 earnings per share estimates for Edesa Biotech in a report issued on Tuesday, January 2nd. Zacks...

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing, and commercializing clinical stage drugs for inflammatory and immune-related diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), EB02 for hemorrhoids, and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.

Volume	10,436.00
52-Wk High	$8.33
52-Wk Low	$2.46

EDSA Edesa Biotech Inc

About

Feed

News

Sentiment

Fundamentals